A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19.
Ray Y, Paul SR, Bandopadhyay P, D'Rozario R, Sarif J, Raychaudhuri D, Bhowmik D, Lahiri A, Vasudevan JS, Maurya R, Kanakan A, Sharma S, Kumar M, Singh P, Roy R, Chaudhury K, Maiti R, Bagchi S, Maiti A, Perwez MM, Mondal A, Tewari A, Mandal S, Roy A, Saha M, Biswas D, Maiti C, Bhaduri R, Chakraborty S, Sarkar BS, Haldar A, Saha B, Sengupta S, Pandey R, Chatterjee S, Bhattacharya P, Paul S, Ganguly D.
Ray Y, et al. Among authors: raychaudhuri d, d rozario r.
Nat Commun. 2022 Jan 19;13(1):383. doi: 10.1038/s41467-022-28064-7.
Nat Commun. 2022.
PMID: 35046397
Free PMC article.
Clinical Trial.